Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial

BACKGROUND: Mexico has one of the highest prevalence rates of obesity worldwide. New pharmacological strategies that focus on people with class III obesity are required. Metformin and dapagliflozin are two drugs approved for the treatment of diabetes. Beyond its effects on glucose, metformin has bee...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Trials
Egile Nagusiak: Ferreira-Hermosillo, Aldo, Molina-Ayala, Mario Antonio, Molina-Guerrero, Diana, Garrido-Mendoza, Ana Pamela, Ramírez-Rentería, Claudia, Mendoza-Zubieta, Victoria, Espinosa, Etual, Mercado, Moisés
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2020
Gaiak:
Study Protocol
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7023779/
https://ncbi.nlm.nih.gov/pubmed/32059692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-020-4121-x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak